Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RESTORE-MASH: A Phase 1/2 Randomized, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of TGM-312-SC01 in Healthy Participants and Adults With MASH

NCT07427680 is registered in ClinicalTrials.gov with Tangram Therapeutics Plc as lead sponsor.

NCT NCT07427680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07427680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RESTORE-MASH: A Phase 1/2 Randomized, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of TGM-312-SC01 in Healthy Participants and Adults With MASH
Lead sponsor
Tangram Therapeutics Plc
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 3, 2026
Completion date
June 30, 2028
Enrollment
99 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants, mash - metabolic dysfunction-associated steatohepatitis